324 related articles for article (PubMed ID: 24346811)
1. Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Yang DS; Seong SJ; Yoon YR; Lim MS; Kwak KH; Lee SJ
J Psychopharmacol; 2014 Apr; 28(4):341-8. PubMed ID: 24346811
[TBL] [Abstract][Full Text] [Related]
2. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
3. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
[TBL] [Abstract][Full Text] [Related]
4. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
5. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
[TBL] [Abstract][Full Text] [Related]
6. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
7. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):873-88. PubMed ID: 22632481
[TBL] [Abstract][Full Text] [Related]
8. Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Canuso CM; Youssef EA; Bossie CA; Turkoz I; Schreiner A; Simpson GM
Int Clin Psychopharmacol; 2008 Jul; 23(4):209-15. PubMed ID: 18545059
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Tzimos A; Samokhvalov V; Kramer M; Ford L; Gassmann-Mayer C; Lim P; Eerdekens M
Am J Geriatr Psychiatry; 2008 Jan; 16(1):31-43. PubMed ID: 18165460
[TBL] [Abstract][Full Text] [Related]
10. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Turkoz I; Bossie CA; Lindenmayer JP; Schooler N; Canuso CM
BMC Psychiatry; 2011 Feb; 11():21. PubMed ID: 21299844
[TBL] [Abstract][Full Text] [Related]
11. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Gattaz WF; Campos JA; Lacerda AL; Henna E; Ruschel SI; Bressan RA; de Oliveira IR; Rocha FL; Grabowski HM; Sacomani E; Louzã MR; Quevedo J; Elkis H; Zorzetto Filho D; Périco Cde A; Lawson FL; Appolinário JC
Curr Med Res Opin; 2014 Apr; 30(4):695-709. PubMed ID: 24289141
[TBL] [Abstract][Full Text] [Related]
12. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Owen RT
Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
[TBL] [Abstract][Full Text] [Related]
14. Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Fu DJ; Bossie CA; Kern Sliwa J; Ma YW; Alphs L
Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):101-9, 109A. PubMed ID: 23446197
[TBL] [Abstract][Full Text] [Related]
15. Paliperidone extended release: a review of its use in the management of schizophrenia.
Chwieduk CM; Keating GM
Drugs; 2010 Jul; 70(10):1295-317. PubMed ID: 20568835
[TBL] [Abstract][Full Text] [Related]
16. Paliperidone extended-release for the treatment of schizophrenia.
Marino J; Caballero J
Pharmacotherapy; 2008 Oct; 28(10):1283-98. PubMed ID: 18823223
[TBL] [Abstract][Full Text] [Related]
17. The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Kim SW; Yoon JS; Kim YS; Ahn YM; Kim CE; Go HJ; Chee IS; Jung SW; Chung YC; Kim YD; Joe S; Lee J; Kwon YJ; Yoon BH; Jae YM
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):228-35. PubMed ID: 22516251
[TBL] [Abstract][Full Text] [Related]
18. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
[TBL] [Abstract][Full Text] [Related]
19. Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Prescrire Int; 2007 Dec; 16(92):236-7. PubMed ID: 18092400
[TBL] [Abstract][Full Text] [Related]
20. Paliperidone: An improvement over risperidone?
Dopheide JA
Am J Health Syst Pharm; 2008 Mar; 65(5):401. PubMed ID: 18281730
[No Abstract] [Full Text] [Related]
[Next] [New Search]